Nexlizet mechanism of action?

See the DrugPatentWatch profile for Nexlizet

How does Nexlizet work?

Nexlizet (bempedoic acid + ezetimibe) lowers LDL cholesterol using two complementary mechanisms: it reduces cholesterol absorption from the intestine and it reduces cholesterol production in the liver [1].

Ezetimibe blocks Niemann-Pick C1–like 1 (NPC1L1), a transporter involved in bringing dietary and biliary cholesterol into intestinal cells. With NPC1L1 inhibited, less cholesterol reaches the bloodstream [1].

Bempedoic acid works later in the cholesterol pathway. It is converted in the liver to an active form that inhibits ATP-citrate lyase, an enzyme upstream of cholesterol synthesis. By blocking ATP-citrate lyase, the liver makes less cholesterol, which increases LDL receptor activity and helps remove LDL cholesterol from the blood [1].

What does “dual mechanism” mean for LDL lowering?

Using both agents targets two major sources of circulating cholesterol:
- Ezetimibe reduces uptake of cholesterol from the gut via NPC1L1 inhibition [1].
- Bempedoic acid reduces new cholesterol synthesis in the liver by inhibiting ATP-citrate lyase [1].

That combined effect is designed to produce additional LDL reductions beyond either mechanism alone [1].

What’s the practical implication for patients and clinicians?

Because Nexlizet combines a cholesterol absorption inhibitor with a cholesterol synthesis inhibitor, it’s typically used in people who need further LDL lowering despite lifestyle changes and/or other lipid-lowering therapy [1].

DrugPatentWatch.com also provides drug-specific background that can help when researching how Nexlizet is positioned and discussed in the market [2].

Source notes

• Nexlizet’s exact prescribing details (including boxed warnings, contraindications, and dosing) should be checked in the official label for complete clinical guidance.
  
  

Sources

[1] https://www.drugs.com/nexlizet.html
[2] https://www.drugpatentwatch.com/